Breakout above previous highs and MA's stacked. Targeting $100
$CRSP is closing the resistance since May 2018. The volume is above the average. watch for rsi resistances as well.
Key Takeaways A descending triangle is a signal for traders to take a short position to accelerate a breakdown. A descending triangle is detectable by drawing trend lines for the highs and lows on a chart. A descending triangle is the counterpart of an ascending triangle, which is another trend line based chart pattern used by technical analysts. Bullish flag...
3 new ipo this week. All of these expected to be good.
Watching this one. Many stocks have entered this parallel channel pattern since the beginning of 2019. Fib channel shows good heartline support. It all depends on what happens with the financial system and stock market in general, but nice swings have been playing out here.
The Megalodon indicators are giving us a buy signal on CRSP Therapeutics! The backtesting results are 100% on this stock so don't miss out on these profits! The Megalodon indicator uses a machine learning algorithm, combined with data from over 500 buy setups, and over 2000 indicators to produce extremely accurate buy signals on any and all asset classes! ...
C wave of the big correction coming up. 20.5 R short have fun
subwave B retraced .5 time for subwave C of B
EDIT and CRSP CRISPR-Cas9, -Cas11, -Cas12 genetic improvements for bio-pharma partnerships The next big thing to improving and repairing defects in you RNA Currently at Fibretracement 0.618 and in spot to move up or down, depending on big money theory...wahahah! but there's enough small money to pull it down, just saying for disclosure.
Anyone who knows me personally is cognisant of the fact that I hail from a pharmacy background that involves managing a community pharmacy in my day-to-day life. While this blog is focused on investing in macroeconomics and having a fundamental macroeconomic outlook, today I am heeding the advice of Peter Lynch; ‘‘you don’t have to go looking for investment...
If you aren't familiar yet with CRISPR technology, check out this Radiolab podcast and then this update.
An inverse head & shoulders pattern formed in the charts of Intellia, a company developing CRISPR gene-editing therapy. While CRISPR has not been approved to begin human trials in the US, it has already been tested on over 80 patients in China. Target: $31 (previous closing high), or long term hold Stop: $18 - $20
Unconventional Median Line on the weekly. Pattern on watch. What is CRISPR? wwwuser.cnb.csic.es Informational only, not a recommendation to buy or sell any security.
Nice support level at $20 Filled Gap up and Gap down. If decent trading volume, long term investors or proponents to CAS-9 research will buy in at these support levels. CRISPR got upgraded. EDITAS holds patents that relate to the use of CRISPR-Cas9 in the cells of humans and other eukaryotes, while the UC Berkeley, Crispr, patents cover use of the gene-editing...